Evidence map›Paper›PMID 27931237›Full record

ArticleJournal of experimental & clinical cancer research : CR2016

A piperazidine derivative of 23-hydroxy betulinic acid induces a mitochondria-derived ROS burst to trigger apoptotic cell death in hepatocellular carcinoma cells.

Nan Yao, Ying-Jie Li, Yu-He Lei, Nan Hu, Wei-Min Chen, Zhe Yao, Miao Yu, Jun-Shan Liu, Wen-Cai Ye, Dong-Mei Zhang

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Replenishment of mitochondrial NaMaterials today. Bio · 2024
    Article
  5. Article
  6. Article
  7. Food science & nutrition · 2024
    Article
  8. Review
  9. Review
  10. Role of Mitophagy in Regulating Intestinal Oxidative Damage.Antioxidants (Basel, Switzerland) · 2023
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Nan YaoCollege of Pharmacy, Jinan University, No.601 West Huangpu Avenue, Guangzhou, 510632, China.
Ying-Jie LiCollege of Pharmacy, Jinan University, No.601 West Huangpu Avenue, Guangzhou, 510632, China.
Yu-He LeiCollege of Pharmacy, Jinan University, No.601 West Huangpu Avenue, Guangzhou, 510632, China.
Nan HuCollege of Pharmacy, Jinan University, No.601 West Huangpu Avenue, Guangzhou, 510632, China.
Wei-Min ChenCollege of Pharmacy, Jinan University, No.601 West Huangpu Avenue, Guangzhou, 510632, China.
Zhe YaoCollege of Pharmacy, Jinan University, No.601 West Huangpu Avenue, Guangzhou, 510632, China.
Miao YuCollege of Pharmacy, Jinan University, No.601 West Huangpu Avenue, Guangzhou, 510632, China.
Jun-Shan LiuSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
Wen-Cai YeCollege of Pharmacy, Jinan University, No.601 West Huangpu Avenue, Guangzhou, 510632, China. chywc@yahoo.com.cn.
Dong-Mei ZhangCollege of Pharmacy, Jinan University, No.601 West Huangpu Avenue, Guangzhou, 510632, China. dmzhang701@foxmail.com.
Jinan University · CNSouthern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundElevated production of reactive oxygen species (ROS) and an altered redox state have frequently been observed in hepatocellular carcinoma (HCC); therefore, selective killing of HCC cells by chemotherapeutic agents that stimulate ROS generation or impair antioxidant systems may be a feasible approach in HCC chemotherapy. Recently, betulinic acid and its derivatives have attracted attention because they showed anti-cancer effects via a ROS- and mitochondria-related mechanism. However, the source of ROS overproduction and the role of mitochondria were poorly identified, and the weak in vivo antitumour activity of these compounds limits their development as drugs.

methodsCytotoxicity was detected using MTT assays. In vivo anti-HCC effects were assessed using nude mice bearing HepG2 tumour xenografts. Cell cycle analysis, apoptosis rate and mitochondrial membrane potential were measured by flow cytometry. ROS production was detected using a microplate reader or a fluorescence microscope. Changes in gene and protein levels were measured by RT-PCR and western blotting, respectively. Other assays were performed using related detection kits.

resultsB5G9, a piperazidine derivative of 23-hydroxy betulinic acid (23-HBA), showed excellent in vivo anti-HCC effects, with a tumour growth inhibitory rate of greater than 80%, and no significant side effects. B5G9 stimulated the production of ROS, which were derived from the mitochondria, but it had no effect on various other antioxidant systems. Moreover, B5G9 induced mitochondrial dysfunction, which was characterized by morphological changes, membrane potential collapse, membrane permeabilization, and decreases in the O

conclusionWe discovered a piperazidine derivative of 23-HBA, B5G9, with excellent anti-HCC effects both in vivo and in vitro and no obvious toxic effects. The underlying mechanism was associated with mitochondria-derived ROS overproduction, and mitochondria played essential roles in B5G9-induced cell death. This study identified a potential agent for anti-HCC therapy and elucidated the mitochondria-related mechanism of BA and its derivatives.

Indexed as

AnimalsCarcinoma, HepatocellularCell Line, TumorCell ProliferationCell SurvivalGene Expression Regulation, NeoplasticHep G2 CellsHumansLiver NeoplasmsMembrane Potential, MitochondrialMiceMitochondriaPiperazinesReactive Oxygen SpeciesTriterpenesXenograft Model Antitumor Assays23-hydroxybetulinic acidPiperazinesReactive Oxygen SpeciesTriterpenesApoptosisBetulinic acidHepatocellular carcinomaMitochondriaReactive oxygen species

Identifiers

PMID27931237
PMCPMC5146873
OpenAlexW2560103221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.